Andres Acosta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8275788/publications.pdf

Version: 2024-02-01

69 papers	2,858 citations	172386 29 h-index	182361 51 g-index
70 all docs	70 docs citations	70 times ranked	2656 citing authors

#	Article	IF	Citations
1	Homeostatic regulation of food intake. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101794.	0.7	19
2	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. International Journal of Obesity, 2022, 46, 555-563.	1.6	16
3	Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging. Brain Sciences, 2022, 12, 431.	1.1	17
4	Evaluation and Management of Patients Referred for Post-Bariatric Surgery Hypoglycemia at a Tertiary Care Center. Obesity Surgery, 2022, 32, 1578-1585.	1.1	3
5	Precision Medicine and Obesity. Handbook of Experimental Pharmacology, 2022, , 467-485.	0.9	5
6	A Protocol for the Cryopreservation of Human Intestinal Mucosal Biopsies Compatible With Single-Cell Transcriptomics and Ex Vivo Studies. Frontiers in Physiology, 2022, 13, .	1.3	2
7	Association between anxiety and eating behaviors in patients with obesity. , 2022, 3, 100021.		4
8	Effects of Heterozygous Variants in the Leptin-Melanocortin Pathway on Roux-en-Y Gastric Bypass Outcomes: a 15-Year Caseâ€“Control Study. Obesity Surgery, 2022, 32, 2632-2640.	1.1	15
9	Weight-centric treatment of depression and chronic pain. , 2022, 3, 100025.		7
10	Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 146-154.e4.	2.4	75
11	Pharmacogenomics of Medicationâ€induced Weight Gain and Antiobesity Medications. Obesity, 2021, 29, 265-273.	1.5	14
12	Precision Medicine and Obesity. Gastroenterology Clinics of North America, 2021, 50, 127-139.	1.0	24
13	Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. Obesity, 2021, 29, 662-671.	1.5	70
14	Gastric Sensory and Motor Functions and Energy Intake in Health and Obesityâ€”Therapeutic Implications. Nutrients, 2021, 13, 1158.	1.7	21
15	Role of enteroendocrine hormones in appetite and glycemia. Obesity Medicine, 2021, 23, 100332.	0.5	7
16	Precision Medicine for Obesity. Digestive Disease Interventions, 2021, 05, 239-248.	0.3	9
17	Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. Seminars in Liver Disease, 2021, 41, 435-447.	1.8	12
18	Association of gastric emptying with postprandial appetite and satiety sensations in obesity. Obesity, 2021, 29, 1497-1507.	1.5	13

#	Article	IF	Citations
19	Contamination of single fluid-filled intragastric balloons with orogastric fluid is not associated with hyperinflation: an ex-vivo study and systematic review of literature. BMC Gastroenterology, 2021, 21, 286.	0.8	3
20	Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet, The, 2021, 398, 1965-1973.	6.3	43
21	Changes in Time of Gastric Emptying After Surgical and Endoscopic Bariatrics and Weight Loss: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 57-68.e5.	2.4	61
22	GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1552-1563.	1.8	60
23	Associations of gastric volumes, ingestive behavior, calorie and volume intake, and fullness in obesity. American Journal of Physiology - Renal Physiology, 2020, 319, G238-G244.	1.6	7
24	Physical activity is associated with accelerated gastric emptying and increased ghrelin in obesity. Neurogastroenterology and Motility, 2020, 32, e13879.	1.6	10
25	Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study. International Journal of Obesity, 2020, 44, 2472-2478.	1.6	16
26	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine, 2020, 55, 102759.	2.7	43
27	Personalization of Endoscopic Bariatric and Metabolic Therapies Based on Physiology: a Prospective Feasibility Study with a Single Fluid-Filled Intragastric Balloon. Obesity Surgery, 2020, 30, 3347-3353.	1.1	21
28	Food intake regulation: Relevance to bariatric and metabolic endoscopic therapies. Techniques and Innovations in Gastrointestinal Endoscopy, 2020, 22, 100-108.	0.4	1
29	Effectiveness of Online Aftercare Programs Following Intragastric Balloon Placement for Obesity Is Similar to Traditional Follow-up: a Large Propensity Matched US Multicenter Study. Obesity Surgery, 2019, 29, 4036-4042.	1.1	4
30	Familial chronic megacolon presenting in childhood or adulthood: Seeking the presumed gene association. Neurogastroenterology and Motility, 2019, 31, e13550.	1.6	8
31	The Gastrointestinal System and Obesity. , 2019, , 43-62.		0
32	Single Fluid-Filled Intragastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population. Clinical Gastroenterology and Hepatology, 2018, 16, 1073-1080.e1.	2.4	61
33	Transoral outlet reduction with full thickness endoscopic suturing for weight regain after gastric bypass: a large multicenter international experience and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 252-259.	1.3	61
34	Combination Therapies for Obesity. Metabolic Syndrome and Related Disorders, 2018, 16, 390-394.	0.5	35
35	Endoscopic Sleeve Gastroplasty Alters Gastric Physiology andÂInduces Loss of Body Weight in Obese Individuals. Clinical Gastroenterology and Hepatology, 2017, 15, 37-43.e1.	2.4	222
36	White Paper AGA: POWER â€" Practice Guide on Obesity andÂWeight Management, Education, and Resources. Clinical Gastroenterology and Hepatology, 2017, 15, 631-649.e10.	2.4	112

#	Article	IF	Citations
37	A working paradigm for the treatment of obesity in gastrointestinal practice. Techniques in Gastrointestinal Endoscopy, 2017, 19, 52-60.	0.3	7
38	Gastrointestinal Complications of Obesity. Gastroenterology, 2017, 152, 1656-1670.	0.6	164
39	Potential mechanisms of effects of serumâ€derived bovine immunoglobulin/protein isolate therapy in patients with diarrheaâ€predominant irritable bowel syndrome. Physiological Reports, 2017, 5, e13170.	0.7	24
40	Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24ÂMonths Follow-Up. Obesity Surgery, 2017, 27, 2649-2655.	1.1	194
41	Current paradigms in the etiology of obesity. Techniques in Gastrointestinal Endoscopy, 2017, 19, 2-11.	0.3	37
42	Endoscopic Treatments for Obesity. Current Treatment Options in Gastroenterology, 2017, 15, 660-675.	0.3	10
43	Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 890-899.	3.7	123
44	Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms. American Journal of Gastroenterology, 2017, 112, 1689-1699.	0.2	67
45	Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health. American Journal of Physiology - Renal Physiology, 2017, 313, G442-G447.	1.6	38
46	Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. American Journal of Physiology - Renal Physiology, 2016, 311, G365-G376.	1.6	25
47	Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2016, 7, e173.	1.3	70
48	Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointestinal Endoscopy, 2016, 83, 48-56.	0.5	26
49	Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut, 2016, 65, 1951-1959.	6.1	101
50	Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. Digestive Diseases and Sciences, 2016, 61, 852-860.	1.1	27
51	Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2016, 40, 1089-1095.	1.3	27
52	Association of UCPâ€3 rs1626521 with obesity and stomach functions in humans. Obesity, 2015, 23, 898-906.	1.5	6
53	A Pilot Study of the Effect of Daikenchuto on Rectal Sensation in Patients with Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2015, 22, 69-77.	0.8	7
54	Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiological Reports, 2015, 3, e12610.	0.7	45

#	Article	IF	Citations
55	<scp>GLP</scp>â€1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity, 2015, 23, 1119-1129.	1.5	74
56	Prokinetics in Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, 97-111.	1.0	89
57	Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. American Journal of Physiology - Renal Physiology, 2015, 309, G10-G20.	1.6	39
58	Pharmacogenetics in irritable bowel syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1187-1191.	1.5	5
59	A Randomized Trial of 5-Hydroxytryptamine4â€"Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. Clinical Gastroenterology and Hepatology, 2015, 13, 701-708.e1.	2.4	25
60	Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy. Gastroenterology, 2015, 148, 537-546.e4.	0.6	143
61	Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. Clinical Gastroenterology and Hepatology, 2015, 13, 2312-2319.e1.	2.4	39
62	Gastrointestinal morbidity in obesity. Annals of the New York Academy of Sciences, 2014, 1311, 42-56.	1.8	31
63	Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut, 2014, 63, 687-695.	6.1	82
64	Association of melanocortin 4 receptor gene variation with satiation and gastric emptying in overweight and obese adults. Genes and Nutrition, 2014, 9, 384.	1.2	16
65	Effect of Increased Bile Acid Synthesis or Fecal Excretion in Irritable Bowel Syndrome-Diarrhea. American Journal of Gastroenterology, 2014, 109, 1621-1630.	0.2	82
66	Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. American Journal of Physiology - Renal Physiology, 2014, 307, G508-G516.	1.6	45
67	Re: Halmos etÂal, A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology, 2014, 146, 1829-1830.	0.6	15
68	Elobixibat and its potential role in chronic idiopathic constipation. Therapeutic Advances in Gastroenterology, 2014, 7, 167-175.	1.4	72
69	The Effect of Caloric Intake and Macronutrient Composition on Intestinal Cholesterol Absorption and Bile Acids in Patients with Obesity. American Journal of Physiology - Renal Physiology, 0, , .	1.6	2